Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GLAC Metabolic Regulatory Probiotics, the Evaluation to Improve the Human Metabolic Syndrome, Intestinal Microflora and Short Chain Fatty Acid.

NCT06183801 is registered in ClinicalTrials.gov with Glac Biotech Co., Ltd as lead sponsor.

NCT NCT06183801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06183801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GLAC Metabolic Regulatory Probiotics, the Evaluation to Improve the Human Metabolic Syndrome, Intestinal Microflora and Short Chain Fatty Acid.
Lead sponsor
Glac Biotech Co., Ltd
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2021
Completion date
March 31, 2023
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome